The companies have entered into a preclinical research collaboration agreement to evaluate the therapeutic potential of combining their two IgG-modulating technologies. The preclinical research collaboration is set up to explore the potential of combining imlifidase, Hansa’s IgG antibody-cleaviAlready a subscriber Login You have read all your free articles, to continue…